+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease



Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease



Pediatric Blood and Cancer 47(5): 589-593



Patients with sickle cell disease (SCD) have high rates of perioperative complications, including bleeding 1,2. We conducted a retrospective review of pre-operative coagulation studies in pediatric patients with SCD followed by a prospective study of 100 well children with SCD to determine the prevalence of abnormal coagulation screening tests, and to evaluate potential etiologies. In the retrospective study, 32/84 (38.1%) had a prolonged prothrombin time (PT), compared to 8/100 in the prospective study. Prolongations of the activated partial thromboplastin time (aPTT) were less common. Children in the prospective study with prolonged PTs had significantly lower levels of Factor V and VII compared to those with normal PTs. Factor VII levels were <50% in 4/8 with long PTs, compared to 3/92 with normal PTs, P=0.001. Though retrospectively, several patients had normalization of their PT with vitamin K, there was no laboratory evidence of vitamin K deficiency in the prospective study. In the retrospective analysis, six of seven children who had pre-operative coagulation studies and significant intraoperative blood loss had prolonged PTs (P=0.04). Children with SCD admitted for surgical procedures were more likely to have prolonged PTs than those tested at a well visit. There was intra-patient variability in coagulation studies that may be related to clinical status, hepatocellular dysfunction, and/or increased clotting factor consumption. Future well-designed prospective studies to determine whether abnormal coagulation studies are associated with an increased risk of perioperative bleeding in children with SCD are necessary.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012457458

Download citation: RISBibTeXText

PMID: 16123995

DOI: 10.1002/pbc.20579


Related references

Prothrombin time and thromboplastin time. On-site measurement of the prothrombin time and activated partial thromboplastin time of surgical patients with laser photometry. Der Anaesthesist 47(4): 295-302, 1998

The influence of time temperature and packed cell on activated partial thromboplastin time and prothrombin time. Thrombosis Research 62(6): 625-634, 1991

Alterations of prothrombin time and activated partial thromboplastin time in dogs with hepatic disease. American Journal of Veterinary Research 42(12): 2053-2056, 1981

Evaluation of a point-of-care coagulation analyzer for measurement of prothrombin time, activated partial thromboplastin time, and activated clotting time in dogs. American Journal of Veterinary Research 62(9): 1455-1460, 2001

Effect of freezing plasma at -20°C for 2 weeks on prothrombin time, activated partial thromboplastin time, dilute Russell viper venom time, activated protein C resistance, and D-dimer levels. Clinical and Applied Thrombosis/Hemostasis 21(1): 41-47, 2015

Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease. American Journal of Human Genetics 91(1): 152-162, 2012

How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clinic Proceedings 82(7): 864-873, 2007

Effect of amiodarone on bleeding time prothrombin time and activated partial thromboplastin time in rats. Ciencia e Cultura (Sao Paulo) 39(5-6): 554-556, 1987

Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis 30(3): 123-130, 2000

Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood Coagulation & Fibrinolysis 15(8): 693-697, 2004

The effect of fluorescent humic substances existing in the well water of Blackfoot disease endemic areas in Taiwan on prothrombin time and activated partial thromboplastin time in vitro. Thrombosis Research 57(5): 747-753, 1990

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thrombosis and Haemostasis 91(6): 1137-1145, 2004

Influence of 8 and 24-h storage of whole blood at ambient temperature on prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time, antithrombin and D-dimer. Blood Coagulation and Fibrinolysis 22(3): 215-220, 2011

Effects of haemolysis, lipaemia and bilirubinaemia on prothrombin time, activated partial thromboplastin time and thrombin time in plasma samples from healthy dogs. Research in Veterinary Science 67(3): 273-276, 1999

One-stage prothrombin time, activated partial thromboplastin time, thrombin time, fibrin degradation product concentration, and antithrombin activity in healthy adult alpacas. Veterinary Clinical Pathology 40(2): 195-197, 2011